ArcticZymes appoints Brenntag as exclusive European bioprocess nuclease distributor

ArcticZymes Technologies ASA has signed an exclusive distribution agreement with Brenntag Specialties Pharma, appointing Brenntag as the sole European distributor for its SAN-HQ and M-SAN enzyme products. This strategic move, effective October 29, 2025, aims to boost the accessibility of ArcticZymes' innovative salt-active nucleases across Europe, particularly for rapidly growing bioprocessing applications like gene therapy and vaccine manufacturing. ArcticZymes will maintain direct customer relationships in the region.

The SAN-HQ and M-SAN enzymes, available in research and GMP-grade formats, are designed for superior performance in physiological and high-salt conditions, ensuring efficient nucleic acid removal in complex manufacturing environments. M-SAN is optimized for physiological salt concentrations, while SAN-HQ is engineered for applications requiring specific salt concentrations to reduce aggregates.

Paul Blackburn, chief commercial officer at ArcticZymes Technologies, emphasized Brenntag's strong regional footprint and technical expertise as crucial for accelerating growth. Joakim Rehné, regional president, Brenntag Pharma EMEA, noted that this partnership strengthens Brenntag's biopharmaceutical portfolio, allowing them to support customers from early research through to full commercialization.